Sovaldi, a newly approved drug to treat Hepatitis C, could see between $5 billion and $9 billion in sales during its first year on the market, one of the largest sales for a new drug’s first year, ...

Sovaldi (sofosbuvir) is a prescription drug used in combination with other drugs to treat chronic hepatitis C virus (HCV). It comes as an oral tablet and pellets. It’s usually taken once daily.

Two high-ranking senators have sent a letter to Foster City, Calif.-based Gilead Sciences demanding answers regarding the $1,000 a pill price tag for hepatitis C drug Sovaldi. The typical 12-week drug ...

In December 2013, the FDA approved Sovaldi a drug developed by Gilead Sciences that promises to do wonders for patients with hepatitis C. Since then, insurers and the government have grown incredibly ...

The breakthrough hepatitis drug Sovaldi has sparked a vigorous debate about the financial sustainability of U.S. healthcare and the role of government in regulating prices. The biggest problem with ...

Sovaldi (sofosbuvir) can cause side effects that range from mild to serious. More common side effects include fatigue and headache. If side effects from Sovaldi become difficult to tolerate, talk with ...

Oct. 23--Sometimes Jane Blumenfeld feels like if she were in prison, she would have a better chance at getting life-saving drugs to treat her liver disease. Blumenfeld is one of 33,160 in California ...

The U.S. Food and Drug Administration, or FDA, on Friday approved Sovaldi (sofosbuvir) developed by Gilead Sciences for treating Hepatitis C VIrus. Gilead Sciences The U.S. Food and Drug ...

– First Regimen for Patients Awaiting Liver Transplantation to Prevent HCV Recurrence – FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food ...

Sign up for the daily CJR newsletter. When we first took a look at media coverage of Sovaldi, the new wonder drug to treat hepatitis C, late last year, reporters were ...

NEW YORK/LOS ANGELES (Reuters) - Shocked by the rapid adoption of a new $84,000 hepatitis C treatment, U.S. health insurers are trying to make sure they aren’t blindsided by other drugs being ...